As filed with the Securities and Exchange Commission on February 5, 2020

Registration No. 333-235951            

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

aTyr Pharma, Inc.

(Exact name of Registrant as specified in its charter)

 

 

Delaware

 

2836

 

20-3435077

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

3545 John Hopkins Court, Suite 250

San Diego, CA 92121

(858) 731-8389

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

Sanjay S. Shukla, M.D., M.S.

President and Chief Executive Officer

aTyr Pharma, Inc.

3545 John Hopkins Court, Suite 250

San Diego, CA 92121

(858) 731-8389

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Sean M. Clayton

Alexa M. Ekman

Cooley LLP

4401 Eastgate Mall

San Diego, CA 92121

(858) 550-6000

Ivan Blumenthal, Esq.

Cliff M. Silverman, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Chrysler Center, 666 3rd Avenue

New York, NY

(212) 935-1300

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box:  

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  333-235951

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

  

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  

 

This post-effective amendment shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.

 

 


 

 

EXPLANATORY NOTE

 

This Post-Effective Amendment No. 1 (this “Amendment”) relates to the Registrant’s Registration Statement on Form S-1 (File No. 333-235951), as amended, declared effective on February 5, 2020 by the Securities and Exchange Commission. The Registrant is filing this Amendment for the sole purpose of replacing Exhibit 5.1 to the Registration Statement. This Amendment does not modify any provision of Part I or Part II of the Registration Statement other than Item 16(a) of Part II as set forth below.

 

 


 

 

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits.

 

 

 

Incorporated by Reference

 

Exhibit

Number

Exhibit Title

Form

File No.

Exhibit

Filing Date

 

 

 

 

 

 

5.1

Opinion of Cooley LLP

 

 

 

Filed herewith

23.2

Consent of Cooley LLP (included in Exhibit 5.1 hereto)

 

 

 

Filed herewith

24.1

Powers of Attorney

S-1

333-235951

24.1

January 17, 2020

 

 

 

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 1 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 5, 2020.

 

 

 

 

 

 

ATYR PHARMA, INC.

 

 

By:

 

/s/ Sanjay S. Shukla, M.D., M.S.

 

 

Sanjay S. Shukla, M.D., M.S.

President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

 

 

 

 

 

Signature

  

Title

 

Date

 

 

 

/s/ Sanjay S. Shukla, M.D., M.S.

Sanjay S. Shukla, M.D., M.S.

  

President, Chief Executive Officer and Director (Principal

Executive Officer)

 

February 5, 2020

 

 

 

/s/ Jill M. Broadfoot

Jill M. Broadfoot

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

February 5, 2020

 

 

 

/s/ *

John K. Clarke

  

Chairman of the Board and Director

 

February 5, 2020

 

 

 

/s/ *

James C. Blair, Ph.D.

  

Director

 

February 5, 2020

 

 

 

/s/ *

Timothy P. Coughlin

  

Director

 

February 5, 2020

 

 

 

 

 

/s/ *

 

Director

 

February 5, 2020

Jane A. Gross, Ph.D.

  

 

 

 

 

 

 

/s/ *

Jeffrey S. Hatfield

  

Director

 

February 5, 2020

 

 

 

/s/ *

Svetlana Lucas, Ph.D.

  

Director

 

February 5, 2020

 

 

 

/s/ *

Paul Schimmel, Ph.D.

  

Director

 

February 5, 2020

 

 

 

* By: /s/ Sanjay S. Shukla, M.D., M.S.

 

 

Sanjay S. Shukla, M.D., M.S.

 

 

Attorney-in-fact

 

 

 

 

aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more aTyr Pharma Charts.
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more aTyr Pharma Charts.